Search results: (10000)
News Different doses of LMWH in hospitalized patients with COVID-19 – interim experience
Many experts recommend administering heparin to patients with COVID-19 as part of anticoagulant prophylaxis, especially in severe forms of this infection. However, data on dosage, administration duration, and the effectiveness of this approach are limited. Therefore, authors from Bologna, Italy, investigated the relationship between various doses of low-molecular-weight heparin (LMWH) and mortality in patients hospitalized with COVID-19.
News Rapid Strengthening and Long-term Stabilization – New Strategy for Sequential Treatment of Severe Osteoporosis
Osteoanabolics have long been considered a treatment modality for osteoporosis that is only considered when antiresorptive medication lacks the desired efficacy. However, their role has been shifting in recent years based on new findings from clinical research, as evidenced by the conclusions of the expert working group of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis, and Musculoskeletal Diseases (ESCEO), whose brief summary we bring.
News Bacterial Biofilm as a Complication of Respiratory Disease Treatment
One of the unique characteristics of certain microorganisms is their ability to form organized communities enveloped in extracellular polymeric matrix and firmly attached to a solid surface or interphase or forming aggregates, collectively referred to as biofilm. Clinically, the major issue is the formation of pathogenic and conditionally pathogenic organisms' biofilm on tissues (such as respiratory tracts) or the surfaces of various medical devices (including catheters and implants), as it represents a dangerous complication leading to the development of chronic, recurrent, and scarcely treatable conditions.
News Vaccination and ALEmtuzumab: ALE when?
When, why and against what should patients with multiple sclerosis treated with alemtuzumab be vaccinated? And is vaccination effective in this population?
News Pharmacokinetics and Safety Profile of Bilastine in Patients Aged 6–11 Years – Findings from Post-hoc Analysis of Studies
The second-generation antihistamine bilastine is approved in Europe for the treatment of allergic rhinoconjunctivitis and urticaria in children over 6 years old. Post-hoc analyses of two clinical studies focused on its safety profile and pharmacokinetics in the pediatric population.
News How did alemtuzumab fare in real clinical practice?
A study published by authors from the University of Massachusetts in January this year in the journal Multiple Sclerosis and Related Disorders focused on the effectiveness and safety of alemtuzumab. How did it fare in real clinical practice?
News LDL cholesterol: a new risk factor for the onset of venous thromboembolic disease?
Not only do atherosclerotic plaques in the arteries and the risk of heart attack decrease along with LDL cholesterol levels. Results from a large molecular genetic study suggest that lowering its levels might also reduce the risk of venous thromboembolic disease.
News COPD is Treated Differently Across Europe – What Could Be the Reasons for This Variability?
As part of this year's Hradec Pneumological Days (HPD 2022), the head of the Pulmonary Clinic at Charles University Faculty of Medicine and University Hospital Hradec Králové, Assoc. Prof. Vladimír Koblížek, M.D., Ph.D., reflected on the different rates of prescription of mucoactive drugs to COPD patients in various European countries. According to him, it is clear that in real practice, this treatment works. So what is the reason for its varying prescription across the old continent?
News Why can probiotics and vitamin D significantly affect human health?
Vitamin D deficiency is the most common hypovitaminosis in developed countries. It is largely related to a lack of outdoor activity. Additionally, the typical Western diet does not support a healthy composition of the gut microbiome. Gut dysbiosis, in turn, is associated with both intestinal and systemic diseases. Alongside a healthy lifestyle, probiotics and oral vitamin D supplementation offer solutions.
News Economic Costs and Concomitant FVIII Consumption in Hemophilia Patients Treated with Emicizumab in the 1st Year − A US Experience
The authors of a recent study, summarizing real-world experience from the US, focused on the concomitant consumption of FVIII (Factor VIII) concentrates during emicizumab prophylaxis and the financial costs in the first year after starting emicizumab treatment.
News Experience from Clinical Practice with Intestinal Gel LECIG in Treating Parkinson's Disease
A Swedish observational study evaluated the applicability of the LECIG intestinal gel, which contains levodopa (20 mg/ml), carbidopa (5 mg/ml), and entacapone (20 mg/ml), in clinical practice for patients with Parkinson's disease.
News Development and Benefits of Intestinal Gel LECIG for Patients with Parkinson's Disease
Patients with advanced Parkinson's disease, for whom the current regimen of orally and transdermally administered medications is insufficient for symptom relief, now have a new treatment option. It involves the continuous administration of an intestinal gel that combines three effective antiparkinsonian drugs.
News Untreated Bleeding in Hemophilia A – An Underestimated Problem? To What Extent?
How common is bleeding in hemophilia A that ultimately goes untreated? This was the focus of a recent study, the results of which were published in the journal Research and Practice in Thrombosis and Hemostasis.
News Can the Treatment of Hypertension Prevent Recurrence of Atrial Fibrillation?
Atrial fibrillation (Afib) is the most common serious heart rhythm disorder and is responsible for a significant portion of deaths in the population. Hypertension is the most common and potentially modifiable risk factor for Afib. A newly published meta-analysis compares the effect of angiotensin receptor antagonism and calcium channel blockade on Afib recurrence in patients with hypertension and Afib.
News Meta-analysis of Efficacy and Safety of Antidiabetics in Treating Gestational DM
What efficacy and safety do insulin, metformin, or the sulfonylurea derivative glibenclamide (glyburide) offer in lowering glucose levels in women with gestational diabetes? The authors of a meta-analysis of randomized controlled trials used a probabilistic model – a Bayesian network – to answer this question.
News Meta-analysis of the efficacy and safety of dupilumab in the treatment of atopic dermatitis in children and adults
Moderate to severe atopic dermatitis (AD) is accompanied by strong inflammatory processes that can occur anywhere on the skin, intense itching, and pain. The biologic dupilumab is a promising molecule for the treatment of severe forms of this condition – results from a recently published meta-analysis indicate that this therapy is not only effective but also well-tolerated by patients.
News Dupilumab in the Treatment of Adolescent Patients with Severe and Refractory Atopic Dermatitis
An open multicenter study evaluating dupilumab in the treatment of moderate to severe atopic dermatitis in adolescents confirmed its long-term efficacy and safety in this age group. In addition to its results, we also summarize information on dosing and reimbursement conditions in the Czech Republic for the age group 12-18 years.
News Current Trends in Proton RT of Head and Neck Tumors: Aiming to Preserve T Lymphocytes, Without Them, Treatment is Ineffective
Tumors of the head and neck are often diagnosed at an advanced stage. With the availability of modern treatments, such as immunotherapy or radiotherapy modalities, prognosis and chances for long-term survival are improving. We discuss trends not only in proton therapy for oropharyngeal tumors and the prospects of combining treatment methods for these diagnoses with the head doctor of the Proton Center Prague Associate Professor MUDr. Jiří Kubeš, Ph.D.
News Lurasidone in a Patient with Paranoid Schizophrenia and Asperger's Syndrome – A Case Study
Lurasidone is an effective and very gentle antipsychotic which is establishing a prominent position in modern psychopharmacotherapy. Its unique receptor profile makes it a suitable choice for hyperprolactinemia induced by risperidone. A significant benefit of lurasidone is its favorable cardiometabolic profile. Switching from another antipsychotic to lurasidone can be performed on an outpatient basis. Most importantly, it is essential to highlight its effect on both positive and negative symptoms of schizophrenia, as demonstrated by the presented case study.
News The safety of dupilumab allows treatment of atopic dermatitis without routine laboratory monitoring
The first comprehensive analysis of laboratory data from 3 clinical trials with dupilumab assessed the incidence of clinically significant changes in hematological or biochemical parameters in patients with moderate to severe atopic dermatitis.
News Risk of Subsequent Fractures in Postmenopausal Women After Initial Fracture
Osteoporosis is associated with an increased risk of fractures. The prospective analysis presented below examined the risk of subsequent fractures in postmenopausal women after an initial fracture depending on its location.
News Prediabetes as a Risk Factor for Overall Mortality and Development of CVD
Prediabetes represents a glucose metabolism disorder with a high risk of developing diabetes. According to the expert panel of the American Diabetes Association (ADA), this risk is up to 70%. A recently published meta-analysis confirms that prediabetes is a significant risk factor for mortality and the development of cardiovascular (CV) diseases not only in the general population but also in patients with known CV disease, and its treatment should therefore be part of cardiovascular prevention.
News How do patients perceive the change in appearance of chronically used medications and to what extent does it lead to non-adherence to therapy?
Doctors regularly encounter patients in their offices who complain about changes in the appearance of their chronically used medications. Such a change can even be the cause of non-adherence to treatment. Interesting findings on this topic were brought by an American survey aimed at identifying the preferences, experiences, and reactions of patients and pharmacists related to changes in the appearance of medications.